NasdaqGS:BIIBBiotechs
The Bull Case For Biogen (BIIB) Could Change Following New Zorevunersen and BIIB142 Pipeline Milestones
In recent days, Stoke Therapeutics and Biogen announced new long-term clinical data supporting the efficacy and safety profile of zorevunersen for Dravet syndrome, while C4 Therapeutics disclosed that Biogen's investigational new drug application for BIIB142 in autoimmune diseases was accepted by the FDA. These product-related updates highlight Biogen's ongoing expansion in neuroscience and autoimmune disease pipelines, underpinned by key scientific collaborations and regulatory...